Predictive Value of Platelet-to-Lymphocyte and Neutrophil-to-Lymphocyte ratio in HCC Treated with Sorafenib and Radioembolization

•Platelet-to-lymphocyte ratio is a predictive factor in patients with advanced HCC.•In patients with a high platelet-to-lymphocyte ratio, patients who receive SIRT+Sorafenib treatment has significantly longer overall survival than patients receive sorafenib monotherapy.•In patients with low platelet-to-lymphocyte ratio, there is no significant difference in overall survival between treatment arms.